These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 34587971)

  • 1. Behavioral effects of different contraceptive methods and HIV acquisition: an ancillary study of the ECHO randomized trial.
    Singata-Madliki M; Lawrie TA; Balakrishna Y; d'Hellencourt FC; Hofmeyr GJ
    Reprod Health; 2021 Sep; 18(1):192. PubMed ID: 34587971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
    Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
    Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of depot medroxyprogesterone acetate, the copper IUD and the levonorgestrel implant on testosterone, sex hormone binding globulin and free testosterone levels: ancillary study of the ECHO randomized clinical trial.
    Hofmeyr GJ; Singata-Madliki M; Batting J; Balakrishna Y; Morroni C
    BMC Womens Health; 2024 Mar; 24(1):167. PubMed ID: 38459552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial.
    Hofmeyr GJ; Singata-Madliki M; Batting J; Steyn P; Thomas KK; Issema R; Beesham I; Mbatsane E; Morrison C; Deese J; Smit J; Philip N; Palanee-Phillips T; Reddy K; Onono M; Mastro TD; Baeten JM;
    PLoS One; 2024; 19(5):e0299802. PubMed ID: 38722832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression.
    Morrison CS; Hofmeyr GJ; Thomas KK; Rees H; Philip N; Palanee-Phillips T; Nanda K; Nair G; Onono M; Mastro TD; Lind M; Heffron R; Edward V; Deese J; Beksinska M; Beesham I; Stringer JSA; Baeten JM; Ahmed K;
    AIDS Res Hum Retroviruses; 2020 Aug; 36(8):632-640. PubMed ID: 32394723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial.
    Mugo NR; Stalter RM; Heffron R; Rees H; Scoville CW; Morrison C; Kourtis AP; Bukusi E; Beksinka M; Philip NM; Beesham I; Deese J; Edward V; Donnell D; Baeten JM;
    Clin Infect Dis; 2022 Sep; 75(4):586-595. PubMed ID: 34910143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Depot Medroxyprogesterone Acetate Intramuscular Injection, Copper Intrauterine Device and Levonorgestrel Implant Contraception on Estradiol Levels: An Ancillary Study of the ECHO Randomized Trial.
    Ryan R; Mussa A; Singtaa-Madliki M; Batting J; Balakrishna Y; Morroni C; Hofmeyr GJ
    Front Glob Womens Health; 2022; 3():887541. PubMed ID: 35669313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contraceptive method preference and reasons for contraceptive discontinuation among women randomized to intramuscular depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant: Findings from Durban, South Africa.
    Beesham I; Bosman S; Beksinska M; Scoville CW; Smit J; Nanda K
    Contraception; 2022 Apr; 108():37-43. PubMed ID: 34848180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, multicentre, open-label trial.
    Beksinska M; Issema R; Beesham I; Lalbahadur T; Thomas K; Morrison C; Hofmeyr GJ; Steyn PS; Mugo N; Palanee-Phillips T; Ahmed K; Nair G; Baeten JM; Smit J
    EClinicalMedicine; 2021 Apr; 34():100800. PubMed ID: 33898953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-randomization Differences in Condomless Vaginal Sex Among Women Randomized to Intramuscular Depot Medroxyprogesterone Acetate Injections, a Copper Intrauterine Device or a Levonorgestrel Implant in the ECHO Trial.
    Deese J; Chen PL; Gao X; Heffron R; Hobbs M; Lapple D; Jaspan H; Miller A; Nair G; Onono M; Palanee-Phillips T; Reddy K; Steiner MJ
    AIDS Behav; 2023 Mar; 27(3):978-983. PubMed ID: 36357806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Contraception on Genital Cytokines in Women Randomized to Copper Intrauterine Device, Depot Medroxyprogesterone Acetate, or Levonorgestrel Implant.
    Tanko RF; Bunjun R; Dabee S; Jaumdally SZ; Onono M; Nair G; Palanee-Phillips T; Harryparsad R; Happel AU; Gamieldien H; Qumbelo Y; Sinkala M; Scoville CW; Heller K; Baeten JM; Bosinger SE; Burgener A; Heffron R; Jaspan HB; Passmore JAS
    J Infect Dis; 2022 Sep; 226(5):907-919. PubMed ID: 35263421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of three contraceptive methods on depression and sexual function: An ancillary study of the ECHO randomized trial.
    Singata-Madliki M; Carayon-Lefebvre d'Hellencourt F; Lawrie TA; Balakrishna Y; Hofmeyr GJ
    Int J Gynaecol Obstet; 2021 Aug; 154(2):256-262. PubMed ID: 33448029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
    Todd CS; Jones HE; Langwenya N; Hoover DR; Chen PL; Petro G; Myer L
    PLoS Med; 2020 May; 17(5):e1003110. PubMed ID: 32442189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pregnancy incidence among African women in a randomized trial of intramuscular depot medroxyprogesterone acetate (DMPA-IM), a copper intrauterine device (IUDs) or a levonorgestrel (LNG) implant for contraception.
    Onono M; Nanda K; Heller KB; Taylor D; Yacobson I; Heffron R; Kasaro MP; Louw CE; Nhlabasti Z; Palanee-Phillips T; Smit J; Wakhungu I; Gichangi PB; Mugo NR; Morrison C; Baeten JM;
    Contracept X; 2020; 2():100026. PubMed ID: 32577615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight change at 12 months in users of three progestin-only contraceptive methods.
    Vickery Z; Madden T; Zhao Q; Secura GM; Allsworth JE; Peipert JF
    Contraception; 2013 Oct; 88(4):503-8. PubMed ID: 23582238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
    Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant.
    Deese J; Philip N; Lind M; Ahmed K; Batting J; Beksinska M; Edward VA; Louw CE; Onono M; Palanee-Phillips T; Smit JA; Baeten JM; Donnell D; Mastro TD; Mugo NR; Nanda K; Rees H; Morrison C
    Sex Transm Infect; 2021 Jun; 97(4):249-255. PubMed ID: 33208512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out.
    Hapgood JP
    AIDS Res Hum Retroviruses; 2020 May; 36(5):357-366. PubMed ID: 31797677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
    Modesto W; Bahamondes MV; Bahamondes L
    Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychological, behavioural and physiological effects of three long-acting reversible contraception (LARC) methods: protocol for an ancillary study of the ECHO randomised trial.
    Singata-Madliki M; Hofmeyr GJ; Carayon-Lefebvre d'Hellencourt F; Lawrie TA
    BMJ Open; 2017 Nov; 7(11):e019205. PubMed ID: 29133336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.